» Articles » PMID: 27986876

Changes in Insomnia Subtypes in Early Parkinson Disease

Overview
Journal Neurology
Specialty Neurology
Date 2016 Dec 18
PMID 27986876
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To examine the development of factors associated with insomnia in a cohort of originally drug-naive patients with incident Parkinson disease (PD) during the first 5 years after diagnosis.

Methods: One hundred eighty-two drug-naive patients with PD derived from a population-based incident cohort and 202 control participants were assessed for insomnia before treatment initiation and were repeatedly examined after 1, 3, and 5 years. Insomnia was diagnosed according to the Stavanger Sleepiness Questionnaire. The Parkinson's Disease Sleep Scale was used to differentiate sleep initiation problems from problems of sleep maintenance. Generalized estimating equation models were applied for statistical measures.

Results: The prevalence of insomnia in general was not higher in patients with PD compared to controls at the 5-year follow-up. There were changes in the prevalence of the different insomnia subtypes over the 5-year follow-up. The prevalence of solitary problems in sleep maintenance increased from 31% (n = 18) in the drug-naive patients at baseline to 49% (n = 29) after 1 year and were associated with the use of dopamine agonists and higher Montgomery-Åsberg Depression Rating Scale scores. The prevalence of solitary sleep initiation problems decreased continuously from 21% (n = 12) at baseline to 7.4% (n = 4) after 5 years; these were associated with less daytime sleepiness.

Conclusions: The prevalence rates of the different insomnia subtypes changed notably in patients with early PD. The frequency of sleep maintenance problems increased, and these problems were associated with dopamine agonist use and depressive symptoms, while the total number of patients with insomnia remained stable. Our findings reflect the need for early individual assessments of insomnia subtypes and raise the possibility of intervention to reduce these symptoms in patients with early PD.

Citing Articles

Tryptophan metabolism-related gene CYP1B1 serves as a shared biomarker for both Parkinson's disease and insomnia.

Li X, Yu W, Wu J, He W, Cheng Y, Gao K Sci Rep. 2025; 15(1):1362.

PMID: 39779759 PMC: 11711247. DOI: 10.1038/s41598-024-84362-8.


Diagnosis and treatment of autonomic failure, pain and sleep disturbances in Parkinson's disease: guideline "Parkinson's disease" of the German Society of Neurology.

Fanciulli A, Sixel-Doring F, Buhmann C, Krismer F, Hermann W, Winkler C J Neurol. 2025; 272(1):90.

PMID: 39751950 PMC: 11698777. DOI: 10.1007/s00415-024-12730-5.


The effects of deep brain stimulation on sleep: a systematic review and meta-analysis.

Wadhwa A, Pacheco-Barrios N, Tripathy S, Jha R, Wadhwa M, Warren A Sleep Adv. 2024; 5(1):zpae079.

PMID: 39525613 PMC: 11543990. DOI: 10.1093/sleepadvances/zpae079.


Sleep Apnea and Amyotrophic Lateral Sclerosis: Cause, Correlation, Any Relation?.

Ozdinler P Brain Sci. 2024; 14(10).

PMID: 39451992 PMC: 11505663. DOI: 10.3390/brainsci14100978.


Insomnia in Parkinson's Disease: Causes, Consequences, and Therapeutic Approaches.

Duan X, Liu H, Hu X, Yu Q, Kuang G, Liu L Mol Neurobiol. 2024; 62(2):2292-2313.

PMID: 39103716 PMC: 11772535. DOI: 10.1007/s12035-024-04400-4.